{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T09:45:32Z","timestamp":1775555132504,"version":"3.50.1"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T00:00:00Z","timestamp":1736035200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.breast.2025.103875","type":"journal-article","created":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T01:30:03Z","timestamp":1736472603000},"page":"103875","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Advancing treatment choices: CDK4\/6 inhibitor switching in HR+\/HER2- metastatic breast cancer"],"prefix":"10.1016","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2687-6436","authenticated-orcid":false,"given":"Paola","family":"Zagami","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatrice","family":"Taurelli Salimbeni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pier Paolo Maria","family":"Berton Giachetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Scafetta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Lambertini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Di Maio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Curigliano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Criscitiello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saverio","family":"Cinieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2025.103875_bib1","author":"Dattani"},{"key":"10.1016\/j.breast.2025.103875_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2018.00227","article-title":"Recent advances in the treatment of breast cancer","volume":"8","author":"Tong","year":"2018","journal-title":"Front Oncol"},{"key":"10.1016\/j.breast.2025.103875_bib3","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1177\/1758834015608993","article-title":"Optimal management of hormone receptor positive metastatic breast cancer in 2016","volume":"7","author":"Reinert","year":"2015","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.breast.2025.103875_bib4","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s10549-017-4385-3","article-title":"Cyclin-dependent kinase 4\/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib","volume":"166","author":"Kwapisz","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2025.103875_bib5","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.3390\/cancers15061763","article-title":"CDK4\/6 inhibitors\u2014overcoming endocrine resistance is the standard in patients with hormone receptor-positive breast cancer","volume":"15","author":"Nabieva","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.breast.2025.103875_bib6","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","article-title":"Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phas","volume":"17","author":"Cristofanilli","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2025.103875_bib7","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2025.103875_bib8","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","article-title":"Monarch 2: abemaciclib in combination with fulvestrant in women with HR+\/HER2\u2212 advanced breast cancer who had progressed while receiving endocrine therapy","volume":"35","author":"Sledge","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2025.103875_bib9","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/annonc\/mdy155","article-title":"Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer","volume":"29","author":"Hortobagyi","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2025.103875_bib10","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1200\/JCO.23.00137","article-title":"Overall survival with palbociclib plus letrozole in advanced breast cancer","volume":"42","author":"Slamon","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2025.103875_bib11","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS22-PD13-11","article-title":"Abstract PD13-11: PD13-11 final overall survival analysis of monarch 2 : a phase 3 trial of abemaciclib plus fulvestrant in patients with hormone receptor-positive, HER2-negative advanced breast cancer","volume":"83","author":"Llombart-Cussac","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.breast.2025.103875_bib12","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1158\/1078-0432.CCR-21-3032","article-title":"Updated overall survival of ribociclib plus endocrine therapy versus endocrine therapy alone in pre- and perimenopausal patients with HR+\/HER2- advanced breast cancer in MONALEESA-7: a phase III randomized clinical trial","volume":"28","author":"Lu","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.breast.2025.103875_bib13","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/S1470-2045(18)30292-4","article-title":"Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial","volume":"19","author":"Tripathy","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2025.103875_bib14","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1056\/NEJMoa2114663","article-title":"Overall survival with ribociclib plus letrozole in advanced breast cancer","volume":"386","author":"Hortobagyi","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2025.103875_bib15","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1001\/jamaoncol.2019.4782","article-title":"The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor\u2013positive, ERBB2-negative breast cancer that progressed on endocrine therapy\u2014MONARCH 2","volume":"6","author":"Sledge","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.breast.2025.103875_bib16","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1200\/JCO.2018.78.9909","article-title":"Phase III randomized study of ribociclib and fulvestrant in hormone receptor\u2013positive, human epidermal growth factor receptor 2\u2013negative advanced breast cancer: MONALEESA-3 [internet]","volume":"36","author":"Slamon","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2025.103875_bib17","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1911149","article-title":"Overall survival with ribociclib plus fulvestrant in advanced breast cancer","volume":"382","author":"Slamon","year":"2020","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.breast.2025.103875_bib18","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.annonc.2024.04.013","article-title":"Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3","volume":"35","author":"Goetz","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.breast.2025.103875_bib19","doi-asserted-by":"crossref","first-page":"LBA1003","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA1003","volume":"40","author":"Finn","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2025.103875_bib20","doi-asserted-by":"crossref","first-page":"LBA500","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA500","article-title":"Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+\/HER2- early breast cancer: primary results from the phase III NATALEE trial","volume":"41","author":"Slamon","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2025.103875_bib21","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1470-2045(22)00694-5","article-title":"Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial","volume":"24","author":"Johnston","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2025.103875_bib22","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1056\/NEJMoa2305488","article-title":"Ribociclib plus endocrine therapy in early breast cancer","volume":"390","author":"Slamon","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2025.103875_bib23","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1093\/jnci\/djaa071","article-title":"Overall survival of CDK4\/6-inhibitor\u2013based treatments in clinically relevant subgroups of metastatic breast cancer: systematic review and meta-analysis","volume":"112","author":"Schettini","year":"2020","journal-title":"JNCI: J Natl Cancer Inst"},{"key":"10.1016\/j.breast.2025.103875_bib24","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41523-023-00520-7","article-title":"The dilemma of selecting a first line CDK4\/6 inhibitor for hormone receptor-positive\/HER2-negative metastatic breast cancer","volume":"9","author":"Grinshpun","year":"2023","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.breast.2025.103875_bib25","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40265-020-01461-2","article-title":"Inhibiting CDK4\/6 in breast cancer with palbociclib, ribociclib, and abemaciclib: similarities and differences","volume":"81","author":"Braal","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.breast.2025.103875_bib26","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s10637-014-0120-7","article-title":"Preclinical characterization of the CDK4\/6 inhibitor LY2835219: in-vivo cell cycle-dependent\/independent anti-tumor activities alone\/in combination with gemcitabine","volume":"32","author":"Gelbert","year":"2014","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.breast.2025.103875_bib27","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1158\/1078-0432.CCR-13-2846","article-title":"Semi-mechanistic pharmacokinetic\/pharmacodynamic modeling of the antitumor activity of LY2835219, a new cyclin-dependent kinase 4\/6 inhibitor, in mice bearing human tumor xenografts","volume":"20","author":"Tate","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.breast.2025.103875_bib28","doi-asserted-by":"crossref","first-page":"69493","DOI":"10.18632\/oncotarget.17778","article-title":"Preclinical characterization of abemaciclib in hormone receptor positive breast cancer","volume":"8","author":"Torres-Guzm\u00e1n","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.breast.2025.103875_bib29","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1158\/2159-8290.CD-16-0095","article-title":"Efficacy and safety of abemaciclib, an inhibitor of CDK4 and CDK6, for patients with breast cancer, non\u2013small cell lung cancer, and other solid tumors","volume":"6","author":"Patnaik","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.breast.2025.103875_bib30","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1124\/dmd.114.062745","article-title":"Brain exposure of two selective dual CDK4 and CDK6 inhibitors and the antitumor activity of CDK4 and CDK6 inhibition in combination with temozolomide in an intracranial glioblastoma xenograft","volume":"43","author":"Raub","year":"2015","journal-title":"Drug Metabol Dispos"},{"key":"10.1016\/j.breast.2025.103875_bib31","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-000774","volume":"5","author":"Fountzilas","year":"2020","journal-title":"ESMO Open"},{"key":"10.1016\/j.breast.2025.103875_bib32","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s11912-019-0769-3","article-title":"CDK 4\/6 inhibitors in breast cancer: current controversies and future directions","volume":"21","author":"Spring","year":"2019","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.breast.2025.103875_bib33","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s10549-020-06029-y","article-title":"Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials","volume":"186","author":"Goetz","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2025.103875_bib34","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1093\/jnci\/djy109","article-title":"Long-term pooled safety analysis of palbociclib in combination with endocrine therapy for HR+\/HER2- advanced breast cancer","volume":"111","author":"Di\u00e9ras","year":"2019","journal-title":"JNCI: J Natl Cancer Inst"},{"key":"10.1016\/j.breast.2025.103875_bib35","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1056\/NEJMoa1810527","article-title":"Overall survival with palbociclib and fulvestrant in advanced breast cancer","volume":"379","author":"Turner","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2025.103875_bib36","doi-asserted-by":"crossref","first-page":"iii53","DOI":"10.1093\/annonc\/mdz100.017","article-title":"Pooled safety analysis of first-line ribociclib (RIB) plus endocrine therapy (ET) in HR+\/HER2\u2013 advanced breast cancer (ABC)","volume":"30","author":"Tripathy","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2025.103875_bib37","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.annonc.2021.05.353","article-title":"Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival","volume":"32","author":"Slamon","year":"2021","journal-title":"Ann Oncol"},{"issue":"27","key":"10.1016\/j.breast.2025.103875_bib38","article-title":"Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor\u2013positive\/human epidermal growth factor receptor 2\u2013negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies","volume":"22","author":"Ettl","year":"2020","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.breast.2025.103875_bib39","doi-asserted-by":"crossref","DOI":"10.1002\/onco.13691","article-title":"Management of <scp>Abemaciclib\u2010Associated<\/scp> adverse events in patients with hormone receptor\u2010positive, human epidermal growth factor receptor 2\u2010negative advanced breast cancer: safety analysis of <scp>MONARCH<\/scp> 2 and <scp>MONARCH<\/scp> 3","volume":"26","author":"Rugo","year":"2021","journal-title":"Oncol"},{"key":"10.1016\/j.breast.2025.103875_bib40","doi-asserted-by":"crossref","first-page":"e749","DOI":"10.1002\/onco.13684","article-title":"Long-term pooled safety analysis of palbociclib in combination with endocrine therapy for hormone receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer: updated analysis with up to 5 Years of follow-up","volume":"26","author":"Finn","year":"2021","journal-title":"Oncol"},{"key":"10.1016\/j.breast.2025.103875_bib41","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41416-021-01415-9","article-title":"Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer","volume":"125","author":"Burris","year":"2021","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/j.breast.2025.103875_bib42","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.annonc.2022.03.006","article-title":"Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study","volume":"33","author":"Rugo","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2025.103875_bib43","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","article-title":"Ribociclib as first-line therapy for HR-positive, advanced breast cancer","volume":"375","author":"Hortobagyi","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2025.103875_bib44","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","article-title":"Monarch 3: abemaciclib as initial therapy for advanced breast cancer","volume":"35","author":"Goetz","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2025.103875_bib45","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ctrv.2019.01.006","article-title":"Drug-drug interactions in breast cancer patients treated with CDK4\/6 inhibitors","volume":"74","author":"Fogli","year":"2019","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.breast.2025.103875_bib46","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.2147\/PPA.S254934","article-title":"Oncologist and patient preferences for attributes of CDK4\/6 inhibitor regimens for the treatment of advanced\/metastatic HR positive\/HER2 negative breast cancer: discrete choice experiment and best\u2013worst Scaling&lt","volume":"14","author":"Maculaitis","year":"2020","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.breast.2025.103875_bib47","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41416-021-01415-9","article-title":"Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer","volume":"125","author":"Burris","year":"2021","journal-title":"Br J Cancer"},{"key":"10.1016\/j.breast.2025.103875_bib48","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231152843","article-title":"Quality of life with ribociclib versus abemaciclib as first-line treatment of HR+\/HER2\u2212 advanced breast cancer: a matching-adjusted indirect comparison","volume":"15","author":"Rugo","year":"2023","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.breast.2025.103875_bib49","doi-asserted-by":"crossref","first-page":"LBA1001","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA1001","article-title":"Abemaciclib plus fulvestrant vs fulvestrant alone for HR+, HER2- advanced breast cancer following progression on a prior CDK4\/6 inhibitor plus endocrine therapy: primary outcome of the phase 3 postMONARCH trial","volume":"42","author":"Kalinsky","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2025.103875_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103239","article-title":"217P Switching cyclin-dependent kinase inhibitors (CDK4\/6i) in patients with hormone receptor-positive (HR+)\/human epidermal growth factor-negative (HER2-) advanced breast cancer (ABC) who experienced unacceptable toxicity","volume":"9","author":"Benvenuti","year":"2024","journal-title":"ESMO Open"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977625000049?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977625000049?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T11:04:33Z","timestamp":1739271873000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977625000049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":50,"alternative-id":["S0960977625000049"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2025.103875","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advancing treatment choices: CDK4\/6 inhibitor switching in HR+\/HER2- metastatic breast cancer","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2025.103875","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103875"}}